Bausch Health is the former Valeant, a company that grew rapidly thanks to a string of acquisitions that left it with $21 billion in debt, almost $10 billion of which will mature in 2027.

Bausch Health, formerly known as Valeant Pharmaceuticals, is a multinational specialty pharmaceutical company with global ...

There have been rumours for several months that Bausch Health (formerly Valeant Pharmaceuticals), B+L's debt-ridden parent company, which retains an 88% ownership stake in its business ...

Vytulta was one of the main reasons that Valeant bought Bausch+Lomb for $8.7 billion in 2013, and the company had originally hoped to get it on the market in the first half of last year.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...